CN108707151B - 嘧啶并-哒嗪酮化合物及其用途 - Google Patents

嘧啶并-哒嗪酮化合物及其用途 Download PDF

Info

Publication number
CN108707151B
CN108707151B CN201810492306.1A CN201810492306A CN108707151B CN 108707151 B CN108707151 B CN 108707151B CN 201810492306 A CN201810492306 A CN 201810492306A CN 108707151 B CN108707151 B CN 108707151B
Authority
CN
China
Prior art keywords
pyridazin
amino
phenyl
oxo
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810492306.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN108707151A (zh
Inventor
阿拉纳巴堪·文卡特桑
罗格·阿斯特伯里·史密斯
苏布拉马尼亚·霍沙哈利
维贾伊·波特卢里
苏尼尔·库马·帕尼格拉希
维什努·巴塞蒂
卡鲁纳斯里·昆图
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liberty Biology Co.,Ltd.
Original Assignee
Asana Biosciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asana Biosciences LLC filed Critical Asana Biosciences LLC
Publication of CN108707151A publication Critical patent/CN108707151A/zh
Application granted granted Critical
Publication of CN108707151B publication Critical patent/CN108707151B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201810492306.1A 2011-08-23 2012-08-23 嘧啶并-哒嗪酮化合物及其用途 Active CN108707151B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161526525P 2011-08-23 2011-08-23
US61/526,525 2011-08-23
CN201280051788.8A CN103974955B (zh) 2011-08-23 2012-08-23 嘧啶并-哒嗪酮化合物及其用途
PCT/US2012/051980 WO2013028818A1 (en) 2011-08-23 2012-08-23 Pyrimido- pyridazinone compounds and use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280051788.8A Division CN103974955B (zh) 2011-08-23 2012-08-23 嘧啶并-哒嗪酮化合物及其用途

Publications (2)

Publication Number Publication Date
CN108707151A CN108707151A (zh) 2018-10-26
CN108707151B true CN108707151B (zh) 2022-06-03

Family

ID=46829884

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810492306.1A Active CN108707151B (zh) 2011-08-23 2012-08-23 嘧啶并-哒嗪酮化合物及其用途
CN201280051788.8A Active CN103974955B (zh) 2011-08-23 2012-08-23 嘧啶并-哒嗪酮化合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280051788.8A Active CN103974955B (zh) 2011-08-23 2012-08-23 嘧啶并-哒嗪酮化合物及其用途

Country Status (14)

Country Link
US (5) US8729079B2 (enExample)
EP (4) EP4327886A3 (enExample)
JP (1) JP5993010B2 (enExample)
CN (2) CN108707151B (enExample)
BR (1) BR112014003981A2 (enExample)
CA (1) CA2846187A1 (enExample)
DK (2) DK2748166T3 (enExample)
ES (2) ES2690971T3 (enExample)
FI (1) FI3392252T3 (enExample)
HU (1) HUE065564T2 (enExample)
IL (1) IL231082A (enExample)
MX (1) MX361458B (enExample)
PL (1) PL2748166T3 (enExample)
WO (1) WO2013028818A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX361458B (es) * 2011-08-23 2018-12-06 Asana Biosciences Llc Compuestos de pirimido-piridazinona y uso de los mismos.
AR106830A1 (es) * 2015-12-04 2018-02-21 Asana Biosciences Llc Usos de piridazinonas para tratar el cáncer
WO2018187294A1 (en) * 2017-04-03 2018-10-11 Asana Biosciences, Llc Pyrimido-pyridazinone compound combinations, methods, kits and formulations thereof
WO2018201131A1 (en) 2017-04-28 2018-11-01 Asana Biosciences, Llc Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
CN111961035B (zh) * 2019-05-20 2022-11-01 南京科技职业学院 一类含有羟基异喹啉类结构的化合物、药物组合物以及其应用
WO2021027943A1 (zh) * 2019-08-14 2021-02-18 正大天晴药业集团南京顺欣制药有限公司 哒嗪酮并嘧啶类衍生物及其医药用途
CN113583026B (zh) * 2020-04-30 2024-06-14 杭州英创医药科技有限公司 一类含有稠合三环结构的化合物
WO2022002118A1 (zh) * 2020-07-01 2022-01-06 四川海思科制药有限公司 一种并环杂环衍生物及其在医药上的应用
WO2023122662A1 (en) * 2021-12-22 2023-06-29 The Regents Of The University Of California Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase
CA3244694A1 (en) * 2022-02-23 2023-08-31 Assia Chemical Industries Ltd. SOLID FORMS OF GUSACITINIB
WO2023192989A2 (en) * 2022-04-01 2023-10-05 Azkarra Therapeutics, Inc. Phthalazinone compounds as parp7 inhibitors
WO2025024765A1 (en) 2023-07-27 2025-01-30 Libertas Bio, Inc. Solid state forms of gusacitinib
WO2025020171A1 (en) * 2023-07-27 2025-01-30 Libertas Bio, Inc. Crystalline forms of a jak/syk inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3764598A (en) * 1969-09-24 1973-10-09 Takeda Chemical Industries Ltd Pyrimidopyridazine derivatives
EP1970373A1 (en) * 2005-12-02 2008-09-17 Mitsubishi Tanabe Pharma Corporation Alicyclic heterocyclic compound
WO2010038060A1 (en) * 2008-09-30 2010-04-08 Astrazeneca Ab Heterocyclic jak kinase inhibitors
WO2011053861A1 (en) * 2009-10-29 2011-05-05 Genosco Kinase inhibitors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1004223A (en) * 1972-05-12 1977-01-25 Theodor Denzel Amino derivatives of pyrido(2,3-d)pyridazine carboxylic acids and esters
JPS4948695U (enExample) 1972-07-29 1974-04-27
JPS50101387A (enExample) * 1974-01-16 1975-08-11
CA1052046A (en) 1974-01-21 1979-04-03 American Cyanamid Company Unsymmetrically substituted 1,4-dioxane-2,5-diones
US5369086A (en) 1993-04-28 1994-11-29 Zeneca Limited N-benzotriazoles
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
JPH0948695A (ja) 1995-08-02 1997-02-18 Toshiba Ceramics Co Ltd シリコン単結晶の製造方法
WO1999043671A1 (en) 1998-02-25 1999-09-02 Pharmacia & Upjohn Company Substituted aminomethyl isoxazoline derivatives useful as antimicrobials
KR100658489B1 (ko) 1998-11-10 2006-12-18 얀센 파마슈티카 엔.브이. Ｈｉｖ 복제를 억제하는 피리미딘
CA2422054C (en) * 2000-09-22 2011-01-11 Akzo Nobel Nv Bicyclic heteroaromatic compounds
JP2004528349A (ja) 2001-04-30 2004-09-16 グラクソ　グループ　リミテッド 副腎皮質刺激ホルモン放出因子（ｃｒｆ）のアンタゴニストとしての縮合ピリミジン類
AU2003212634A1 (en) 2002-03-11 2003-09-22 Zetiq Technologies Ltd. Compounds useful in the treatment of cancer
MXPA05001096A (es) 2002-07-29 2005-11-23 Rigel Pharmaceuticals Inc Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
US7550590B2 (en) 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
AU2004265288A1 (en) 2003-07-30 2005-02-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
TW200538120A (en) 2004-02-20 2005-12-01 Kirin Brewery Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same
RU2405778C2 (ru) 2004-09-30 2010-12-10 Тиботек Фармасьютикалз Лтд. 5-гетероциклилпиримидины, ингибирующие вич
US7795275B2 (en) 2004-12-24 2010-09-14 Uniquest Pty Limited Method of treatment or prophylaxis
JP2008534479A (ja) 2005-03-25 2008-08-28 テイボテク・フアーマシユーチカルズ・リミテツド Ｈｃｖの複素二環式阻害剤
WO2006105063A1 (en) 2005-03-25 2006-10-05 Scios Inc. Heterobicylic inhibitors of tgfbeta
DE602006007832D1 (de) 2005-04-29 2009-08-27 Janssen Pharmaceutica Nv Benzotriazolderivate als cannabinoidrezeptorantagonisten
US20070161670A1 (en) 2006-01-09 2007-07-12 Bristol-Myers Squibb Company Process for the preparation of substituted heterocycles
JP2009535393A (ja) 2006-05-01 2009-10-01 ファイザー・プロダクツ・インク 置換２−アミノ縮合複素環式化合物
GB0625196D0 (en) 2006-12-18 2007-01-24 7Tm Pharma As Modulators of cannabinoid receptor
CN103690542B (zh) * 2006-12-28 2015-11-18 Abbvie公司 聚(adp-核糖)聚合酶抑制剂
GEP20135925B (en) 2007-03-14 2013-10-10 Exelixis Patent Co Llc Inhibitors of hedgehog pathway
TW200942537A (en) 2008-02-01 2009-10-16 Irm Llc Compounds and compositions as kinase inhibitors
AR073760A1 (es) 2008-10-03 2010-12-01 Astrazeneca Ab Derivados heterociclicos y metodos de uso de los mismos
AR073949A1 (es) 2008-10-21 2010-12-15 Metabolex Inc Agonistas del receptor aril-gpr120 y usos de los mismos
TW201130852A (en) * 2009-12-23 2011-09-16 Abbott Lab Novel thienopyrrole compounds
WO2012058671A1 (en) 2010-10-31 2012-05-03 Endo Pharmaceuticals Inc. Substituted quinazoline and pyrido-pyrimidine derivatives
MX361458B (es) * 2011-08-23 2018-12-06 Asana Biosciences Llc Compuestos de pirimido-piridazinona y uso de los mismos.
WO2014022728A1 (en) 2012-08-02 2014-02-06 Endo Pharmaceuticals, Inc Substituted 5 - (quinazolin - 2 - yl) pyrimidin- 2 -amine derivatives useful as pi3k/mtor inhibitors for the treatment of cancer
AR106830A1 (es) * 2015-12-04 2018-02-21 Asana Biosciences Llc Usos de piridazinonas para tratar el cáncer
WO2018201131A1 (en) * 2017-04-28 2018-11-01 Asana Biosciences, Llc Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3764598A (en) * 1969-09-24 1973-10-09 Takeda Chemical Industries Ltd Pyrimidopyridazine derivatives
EP1970373A1 (en) * 2005-12-02 2008-09-17 Mitsubishi Tanabe Pharma Corporation Alicyclic heterocyclic compound
WO2010038060A1 (en) * 2008-09-30 2010-04-08 Astrazeneca Ab Heterocyclic jak kinase inhibitors
WO2011053861A1 (en) * 2009-10-29 2011-05-05 Genosco Kinase inhibitors

Also Published As

Publication number Publication date
EP4327886A2 (en) 2024-02-28
MX2014002112A (es) 2014-09-25
JP5993010B2 (ja) 2016-09-14
ES2690971T3 (es) 2018-11-23
WO2013028818A1 (en) 2013-02-28
DK3392252T3 (da) 2024-01-08
CN108707151A (zh) 2018-10-26
IL231082A0 (en) 2014-03-31
DK2748166T3 (en) 2018-10-29
EP2748166B1 (en) 2018-07-11
PL2748166T3 (pl) 2019-05-31
US20200190095A1 (en) 2020-06-18
CN103974955A (zh) 2014-08-06
US20140221315A1 (en) 2014-08-07
BR112014003981A2 (pt) 2017-03-07
US9382277B2 (en) 2016-07-05
EP3404029A2 (en) 2018-11-21
CN103974955B (zh) 2018-06-19
US20190092779A1 (en) 2019-03-28
US20130053346A1 (en) 2013-02-28
US10183944B2 (en) 2019-01-22
FI3392252T3 (fi) 2024-01-08
WO2013028818A8 (en) 2013-09-19
JP2014524475A (ja) 2014-09-22
US20160257691A1 (en) 2016-09-08
ES2969977T3 (es) 2024-05-23
MX361458B (es) 2018-12-06
EP2748166A1 (en) 2014-07-02
EP4327886A3 (en) 2024-05-22
EP3392252A1 (en) 2018-10-24
US8729079B2 (en) 2014-05-20
EP3404029A3 (en) 2018-12-12
EP3392252B1 (en) 2023-10-04
HUE065564T2 (hu) 2024-06-28
US10647720B2 (en) 2020-05-12
CA2846187A1 (en) 2013-02-28
IL231082A (en) 2016-09-29

Similar Documents

Publication Publication Date Title
CN108707151B (zh) 嘧啶并-哒嗪酮化合物及其用途
CN1871240B (zh) 吡咯并嘧啶酮衍生物
SG176461A1 (en) Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
US20080171769A1 (en) Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
ES2999539T3 (en) 1h-benzo[d]imidazole derivatives as tlr9 inhibitors for the treatment of fibrosis
CN102307875A (zh) 吡咯并嘧啶基axl激酶抑制剂
KR20010085824A (ko) 단백질 키나아제 억제제로서의 피롤로피리미딘
US20240166617A1 (en) Phosphoinositide 3 kinase beta inhibitors and compositions and methods thereof
TW201319067A (zh) 三唑并吡啶化合物
WO2018187294A1 (en) Pyrimido-pyridazinone compound combinations, methods, kits and formulations thereof
CN119790043A (zh) 三环类化合物及其应用
US9290503B2 (en) Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
CN111961035B (zh) 一类含有羟基异喹啉类结构的化合物、药物组合物以及其应用
HK40107186A (en) Pyrimido- pyridazinone compounds and use thereof
HK40000773A (en) Pyrimido-pyridazinone compounds and methods and use thereof
HK1262920A1 (en) Pyrimido- pyridazinone compounds and use thereof
HK1262920B (en) Pyrimido- pyridazinone compounds and use thereof
KR20220133874A (ko) 매크로사이클릭 화합물
TW202140474A (zh) 稠合雜芳基類衍生物、其製備方法及其在醫藥上的應用
CN120365268A (zh) 一种靶向hpk1的疏水标签化合物、药物组合物及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20220725

Address after: new jersey

Patentee after: ABS development 1 Co.,Ltd.

Address before: new jersey

Patentee before: Asana BioSciences, LLC

CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: new jersey

Patentee after: Liberty Biology Co.,Ltd.

Address before: new jersey

Patentee before: ABS development 1 Co.,Ltd.